Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
This article was originally published in The Pink Sheet Daily
Executive Summary
New England Journal of Medicine editorial says cost-effectiveness data and head-to-head studies on new oral anticoagulants are needed to move prescribing away from warfarin for atrial fibrillation patients.